News

LOS ANGELES–(BUSINESS WIRE)–Phytecs, Inc., a biotechnology company exploring potential therapies that target the body’s endocannabinoid system (ECS) to treat disease, today announced the addition of new members to the company’s

WASHINGTON–(BUSINESS WIRE)–Phytecs, Inc., a biotechnology company exploring innovative research into and potential treatments targeting the endocannabinoid system (ECS), announced new findings from its study of fluorinated cannabidiol derivatives (F-CBDs) at

Professor Raphael Mechoulam, cannabinoid science pioneer, will lead team testing potential of existing proprietary compounds and identifying new compounds targeting specific elements of ECS LOS ANGELES & JERUSALEM–(BUSINESS WIRE)–Phytecs Inc.,

– Supports Investigation of its HUF-101 Drug Candidate Across a Range of Indications – LOS ANGELES–(BUSINESS WIRE)–Phytecs is expanding its preclinical research program on its novel fluorinated cannabidiol, HUF-101, along

LOS ANGELES–(BUSINESS WIRE)–Compelling evidence that many plant species beyond cannabis interact with the body’s endocannabinoid system (ECS) is presented in Dr. Ethan B. Russo’s new cover story for the July